Study finds socio-economic inequalities in access to novel therapies for many NSCLC patients

Novel anti-cancer therapies were not accessible to more than half of the patients in England who were diagnosed with non-small cell lung cancer, according to a new study published in the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer.

Related Keywords

Adam Todd ,Lily Ramsey ,Professor Of Pharmaceutical Public Health ,Population Health Sciences Institute At Newcastle University ,National Health Service ,Thoracic Oncology ,International Association ,Population Health Sciences Institute ,Newcastle University ,Newcastle Upon Tyne Hospitals ,Systemic Anti Cancer Therapy ,Multiple Deprivation ,Lead Author ,Cancer Epidemiology ,Pharmaceutical Public Health ,Cancer ,Addiction ,Evacizumab ,Biomarker ,Fell ,Healthcare ,Lung Cancer ,Non Small Cell Lung Cancer ,Oncogene ,Ncology ,Research ,Small Cell Lung Cancer ,Humor ,